Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: KENNETH R SANDERS who wrote (462)	1/25/1999 8:11:00 AM
From: John Carragher	Read Replies (1) \| Respond to of 942

Warner-Lambert 4Q Net 40c/Diluted Share Vs 28c Dow Jones Newswires Warner-Lambert Co. - Morris Plains, NJ 4th Quar Dec. 31: 1998 1997 Sales $2,877,900,000 $2,327,400,000 Net income 341,100,000 235,700,000 Shr earns (basic) Net income .42 .29 Shr earns (diluted) Net income .40 .28 Per share figures reflect a 3-for1 stock split effective May 8, 1998. Year Dec. 31: 1998 1997 Sales $10,213,700,000 $8,179,800,000 Net income 1,254,000,000 869,500,000 Shr earns (basic) Net income 1.53 1.07 Shr earns (diluted) Net income 1.48 1.04 Per share amounts reflect a 3-for-1 stock split effective May 8, 1998. Warner-Lambert Co. (WLA) said worldwide sales for the year increased 25% to a record $10.2 billion compared with $8.2 billion in 1997. After adjusting for the unfavorable effects of exchange, sales increased 28%. Unit volume growth for the year was 29%. The company said that "based on current planning assumptions, we are confident that we will realize an increase in diluted earnings per share of 30% in 1999." Warner-Lambert Co. said for the year, worldwide sales in the pharmaceutical segment, the largest of Warner-Lambert's three business segments, increased 55% to $5.6 billion compared with $3.6 billion in 1997. At constant foreign exchange rates, sales rose 57%. In the U.S., worldwide sales sales rose 74% to $3.8 billion. In markets outside the U.S., sales increased 26% - 32% at constant foreign exchange rates - to $1.8 billion. The company said pharmaceutical sales growth was led by Lipitor (atorvastatin calcium). Worldwide sales of Lipitor more than doubled to $2.2 billion in 1998. The company said its oral agent for the treatment of type 2 diabetes, ReZulin (troglitazone) helped pharmaceutical sales for the year. Sales rose 78% to $748 million; sales of anticonvulsant, Neurontin (gabapentin), grew 76% to $514 million; and sales of the antihypertensive Accupril (quinapril), increased 20% to $454 million. Warner-Lambert Co. said for the year, worldwide sales in the pharmaceutical segment, the largest of Warner-Lambert's three business segments, increased 55% to $5.6 billion compared with $3.6 billion in 1997. At constant foreign exchange rates, sales rose 57%. In the U.S., worldwide sales sales rose 74% to $3.8 billion. In markets outside the U.S., sales increased 26% - 32% at constant foreign exchange rates - to $1.8 billion. The company said pharmaceutical sales growth was led by Lipitor (atorvastatin calcium). Worldwide sales of Lipitor more than doubled to $2.2 billion in 1998. The company said its oral agent for the treatment of type 2 diabetes, ReZulin (troglitazone) helped pharmaceutical sales for the year. Sales rose 78% to $748 million; sales of anticonvulsant, Neurontin (gabapentin), grew 76% to $514 million; and sales of the antihypertensive Accupril (quinapril), increased 20% to $454 million.